In conclusion, the findings by our group and others warrant further investigation of combined inhibition of the MAPK and AR pathway at an early stage of systemic treatment of AR-driven prostate cancer to overcome primary or acquired resistance. The gene discussed is AR; the disease is prostate carcinoma.